查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1944421

全球眼科藥品市場按劑型、治療領域、應用、給藥途徑、國家及地區分類－產業分析、市場規模、市佔率及2025-2032年預測

Ophthalmic Drugs Market, By Formulation Type, By Therapeutic Area, By Application, By Route of Administration, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 321 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024年眼科藥品市場規模價值404.5634億美元，從2025年到2032年將以8.45%的複合年成長率成長。

眼科藥物是專門用於識別、治療、預防和管理影響眼部及周圍組織的眼科疾病的醫療產品。專家提供眼藥水、眼膏、凝膠、植體和注射等局部治療方案，確保藥物精準輸送，同時最大限度地減少全身不良反應。眼科藥物可用於治療多種眼部疾病，包括青光眼、乾眼症、結膜炎、葡萄膜炎、老齡化黃斑部病變、糖尿病視網膜病變、眼部感染疾病和眼部發炎。產品包含的活性成分包括抗生素、抗發炎藥、青光眼藥物、抗病毒藥、抗黴菌藥和生物製藥。由於眼部組織需要特殊保護，研究人員制定了嚴格的無菌和安全標準。

眼科藥品市場 - 市場動態

眼科疾病呈上升趨勢

隨著全球眼科疾病發生率的上升，眼科藥品市場也不斷擴張。包括青光眼、白內障、老齡化黃斑部病變、糖尿病視網膜病變、乾眼症和感染性結膜炎在內的各種眼疾發生率持續攀升，對有效眼科治療的需求也隨之增加。全球眼科疾病率的上升是由多種因素造成的，包括人口老化、糖尿病盛行率上升、螢幕使用時間增加、都市化進程加快、環境污染。患者對早期診斷、長期治療和疾病管理的需求，推動了處方箋和非處方藥的需求成長，從而帶動了已開發市場和新興市場眼科藥品市場的持續成長。

例如，根據世界衛生組織（世衛組織）的數據，全球至少有 22 億人因近視或遠視而視力受損，其中 1 億例是可以預防的，但仍未解決。

眼科藥品市場－細分市場分析：

透過使用

2024年，抗發炎藥物佔了相當大的收入佔有率。醫生使用包括皮質類固醇和非類固醇消炎劑眼科藥物來治療多種眼科疾病。由於全球人口老化導致眼科疾病增加、眼科手術量增加以及慢性眼科疾病率上升，對這些治療方法的需求不斷增加。製劑技術的進步，例如無防腐劑眼藥水和緩釋給藥系統，提高了抗發炎藥物的療效、安全性和患者依從性，從而促進了醫生和患者的使用。臨床和技術進步的共同推動了眼科藥品市場中抗發炎藥物類別的收入成長。

透過行政途徑

局部用藥佔市場主導地位。臨床醫生更傾向於使用局部眼科藥物，因為這些藥物可以直接作用於眼表，並即時緩解症狀。局部治療在治療乾眼症、過敏性結膜炎和局部發炎等常見眼科疾病療效顯著，加之新型無防腐劑溶液和改良給藥系統的出現，提高了患者的舒適度和治療依從主導，因此該局部市場一直保持著收入領先地位。這些因素共同推動了局部眼科藥物市場的持續成長。

眼科藥品市場－區域分析

在預測期內，北美將佔據最大的收入佔有率。這一高佔有率主要歸因於兩個因素：視網膜疾病發生率的上升以及該地區政府的優惠政策。北美是一個已開發地區，醫療保健支出龐大。北美市場擴張的原因有兩個：一是需要眼科護理的人數不斷增加，二是眼科手術數量的增加。美國和加拿大需求的成長主要源自於老年人口的成長，因為老年人比年輕人更容易需要眼科照護。此外，該地區糖尿病患者數量的增加也導致了用於治療糖尿病眼科疾病的眼科藥物需求的增加。

目錄

第1章 眼科藥品市場概覽

  • 調查範圍
  • 市場預測期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：眼科藥品市場：主要市場趨勢

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 未來市場趨勢

第4章 眼科藥物治療領域研究

  • PEST分析
  • 波特五力分析
  • 成長前景分析
  • 法規結構分析

第5章 眼科藥品市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章 眼科藥品市場概況

  • 眼科藥品市佔率分析（2024 年）
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

7. 按劑型分類的眼科藥品市場

  • 概述
    • 細分市場佔有率分析：依配方類型
    • 注射
    • 凝膠
    • 軟膏
    • 眼藥水
    • 緩釋製劑

8. 眼科藥品市場依治療領域分類

  • 概述
    • 細分市場佔有率分析：依治療領域分類
    • 視網膜疾病
    • 白內障手術
    • 過敏性結膜炎
    • 感染疾病
    • 眼壓升高

第9章 眼科藥品市場（依應用領域分類）

  • 概述
    • 細分市場佔有率分析：按應用
    • 抗病毒物質
    • 抗生素
    • 消炎（藥）
    • 青光眼
    • 乾眼症

第10章 依給藥途徑分類的眼科藥品市場

  • 概述
    • 細分市場佔有率分析：依管理途徑
    • 局部的
    • 結膜下
    • 玻璃體內注射
    • 全身給藥
    • 眼周

第11章 眼科藥品市場（按地區分類）

  • 介紹
  • 北美洲
    • 概述
    • 北美主要製造商
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲主要製造商
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 其他
  • 亞太地區
    • 概述
    • 亞太地區主要製造商
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 其他
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲的主要製造商
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他

第12章 主要供應商分析－眼科藥品

  • 競爭對手儀錶板
    • 競爭基準
    • 競爭定位
  • 公司簡介
    • Roche（Genentech, Inc.）
    • Regeneron Pharmaceuticals, Inc.
    • Bausch Health Companies, Inc.
    • Merck &Co., Inc.
    • Novartis AG
    • Coherus BioSciences, Inc.
    • AbbVie, Inc.（Allergan）
    • Pfizer, Inc.
    • Bayer AG
    • Santen Pharmaceutical Co., Ltd.
    • Alcon
    • Nicox

第13章：分析師視角

簡介目錄
Product Code: ANV6055

The Ophthalmic Drugs Market size was valued at US$40,456.34 Million in 2024, expanding at a CAGR of 8.45% from 2025 to 2032.

Ophthalmic drugs function as dedicated medical products which enable doctors to identify and treat, prevent, and control eye diseases that affect both the eye and its adjacent tissues. The drugs provide localized treatment through eye drops, ointments, gels, inserts, and ointment and gel and insert and injection methods which specialists use to achieve precise medicine delivery while reducing unwanted effects throughout the body. Ophthalmic drugs provide treatment options for various medical conditions, which include glaucoma, dry eye disease, conjunctivitis, uveitis, age-related macular degeneration, diabetic retinopathy, eye infections, and eye inflammation. The products include active pharmaceutical components which consist of antibiotics and anti-inflammatory drugs, anti-glaucoma medications, antiviral medicines, antifungal agents, and biologic products. Researchers establish strict sterility and safety standards because ocular tissues require special protection.

Ophthalmic Drugs Market- Market Dynamics

Rising prevalence of eye disease

The ophthalmic drugs market is expanding because of the rising number of eye diseases that occur throughout the world. The demand for effective eye treatments remains constant because glaucoma cataracts, age-related macular degeneration, diabetic retinopathy, dry eye disease, and infectious conjunctivitis all show increasing occurrence rates. The worldwide increase of eye disorders results from multiple factors which include population aging and growing diabetes rates, extended screen time, urban living, and environmental pollution. The demand for both prescription and over-the-counter ophthalmic drugs increases as patients need both early diagnosis and extended treatment and disease management which results in continuous market growth for developed nations and emerging markets.

For instance, according to the World Health Organization, globally, at least 2.2 billion people have a near or distance vision impairment.1 billion of these cases involve vision impairment which should have been prevented but remains unresolved.

Ophthalmic Drugs Market- Segmentation Analysis:

By Application

In 2024, the anti-inflammatories held a high revenue share. Doctors use anti-inflammatory ophthalmic drugs which include corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), to treat multiple eye conditions. The worldwide rise in eye diseases because of population aging, increased eye surgeries, and growing chronic eye disease rates has created a higher demand for these treatments. The development of formulation technologies which include preservative-free eye drops and sustained-release delivery systems, has enhanced anti-inflammatory treatment effectiveness, safety, and patient compliance which doctors and patients now use more frequently. The combination of clinical and technological developments leads to increased revenue growth for the anti-inflammatory category of the ophthalmic drugs market.

By Route of Administration

The topical dominates the market. Doctors prefer topical ophthalmic drugs in clinical settings because these medications enable direct eye surface delivery and provide immediate symptom relief. The segment maintains its revenue leadership because topical treatments show high success rates for managing common eye diseases like dry eye and allergic conjunctivitis and postoperative inflammation and new topical formulations with preservative-free solutions and improved delivery systems increase patient comfort and treatment compliance. The ophthalmic drugs market for topical administration methods keeps growing because of these factors.

Ophthalmic Drugs Market- Geographical Insights

North America holds the largest revenue share over the projected period. The high share results from two factors which include the growing occurrence of retinal diseases and the beneficial government programs in the area. North America represents a developed area that spends substantial amounts on healthcare. The North American market expands because of two factors which include the rising number of people who need eye care and the increasing number of eye treatment procedures. The rising demand in the United States and Canada results from the increasing senior population because older people need eye care more than younger people do. The increasing rate of diabetes in the area has created a higher need for ophthalmic drugs that treat diabetic eye conditions.

Ophthalmic Drugs Market- Competitive Landscape:

The ophthalmic drugs market's competitive environment is shaped by various factors, which include large diversified pharmaceutical companies, specialized vision-care businesses, and rapidly developing biologics markets, especially anti-VEGF treatments, ongoing mergers and acquisitions, licensing activities, and increasing competition from generic drugs and biosimilar products. The global leaders in the industry, who include AbbVie (Allergan), Alcon, Bausch + Lomb and Regeneron (with Bayer for Eylea), Novartis, Roche, and Bayer and Santen, sustain their strong market presence through their extensive product offerings and established distribution networks, and their comprehensive research and development programs, which include both small-molecule and biologic ophthalmic treatments.

Recent Developments:

In October 2025, Santen Pharmaceutical Co., Ltd. announced that it launched SETANEO(R) Ophthalmic Solution 0.002% (generic name: sepetaprost; hereafter the product) in Japan, for the treatment of glaucoma and ocular hypertension. The product contains 0.002% sepetaprost, which is a bicyclic prostaglandin derivative that binds to FP and EP3 receptors to increase aqueous humor outflow and decrease intraocular pressure. Santen submitted a manufacturing and marketing authorization application in September 2024 based on Phase III clinical trial results which were conducted in Japan and received approval in August 2025 for glaucoma and ocular hypertension treatment.

In December 2025, Amneal Pharmaceuticals, Inc. declared that the U.S. Food and Drug Administration (FDA) had given its approval to the Company's cyclosporine ophthalmic emulsion 0.05% product which comes as a sterile formulation without preservatives in single-use vials. The product is the generic equivalent of RESTASIS(R) (cyclosporine ophthalmic emulsion) 0.05%, a registered trademark of Allergan, an AbbVie company.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL OPHTHALMIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Roche (Genentech, Inc.)
  • Regeneron Pharmaceuticals, Inc.
  • Bausch Health Companies, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Coherus BioSciences, Inc.
  • AbbVie, Inc. (Allergan)
  • Pfizer, Inc.
  • Bayer AG
  • Santen Pharmaceutical Co., Ltd.
  • Alcon
  • Nicox

GLOBAL OPHTHALMIC DRUGS MARKET, BY FORMULATION TYPE- MARKET ANALYSIS, 2019 - 2032

  • Injectables
  • Gels
  • Ointments
  • Eye Drops
  • Sustained Release

GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Retinal Disorders
  • Cataract Surgery
  • Allergic Conjunctivitis
  • Infectious Diseases
  • Ocular Hypertension

GLOBAL OPHTHALMIC DRUGS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Antiviral
  • Antibiotic
  • Anti-Inflammatory
  • Glaucoma
  • Dry Eye
  • GLOBAL OPHTHALMIC DRUGS MARKET, ROUTE OF ADMINISTRATION - MARKET ANALYSIS, 2019 - 2032
  • Topical
  • Subconjunctival
  • Intravitreal
  • Systemic
  • Periocular

GLOBAL OPHTHALMIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Ophthalmic Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Ophthalmic Drugs Market Snippet by Formulation Type
    • 2.1.2. Ophthalmic Drugs Market Snippet by Therapeutic Area
    • 2.1.3. Ophthalmic Drugs Market Snippet by Application
    • 2.1.4. Ophthalmic Drugs Market Snippet by Route of Administration
    • 2.1.5. Ophthalmic Drugs Market Snippet by Country
    • 2.1.6. Ophthalmic Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Ophthalmic Drugs Key Market Trends

  • 3.1. Ophthalmic Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Ophthalmic Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Ophthalmic Drugs Market Opportunities
  • 3.4. Ophthalmic Drugs Market Future Trends

4. Ophthalmic Drugs Therapeutic Area Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Ophthalmic Drugs Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Ophthalmic Drugs Market Landscape

  • 6.1. Ophthalmic Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Ophthalmic Drugs Market - By Formulation Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Formulation Type, 2024&2032 (%)
    • 7.1.2. Injectables
    • 7.1.3. Gels
    • 7.1.4. Ointments
    • 7.1.5. Eye Drops
    • 7.1.6. Sustained Release

8. Ophthalmic Drugs Market - By Therapeutic Area

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapeutic Area, 2024&2032 (%)
    • 8.1.2. Retinal Disorders
    • 8.1.3. Cataract Surgery
    • 8.1.4. Allergic Conjunctivitis
    • 8.1.5. Infectious Diseases
    • 8.1.6. Ocular Hypertension

9. Ophthalmic Drugs Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2024&2032 (%)
    • 9.1.2. Antiviral
    • 9.1.3. Antibiotic
    • 9.1.4. Anti-Inflammatory
    • 9.1.5. Glaucoma
    • 9.1.6. Dry Eye

10. Ophthalmic Drugs Market - By Route of Administration

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Route of Administration, 2024&2032 (%)
    • 10.1.2. Topical
    • 10.1.3. Subconjunctival
    • 10.1.4. Intravitreal
    • 10.1.5. Systemic
    • 10.1.6. Periocular

11. Ophthalmic Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024&2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
    • 11.2.4. North America Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
    • 11.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
    • 11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
    • 11.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.2.8.3. U.S. Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.2.8.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.2.8.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.2.9.3. Canada Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.2.9.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.2.9.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Ophthalmic Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
    • 11.3.4. Europe Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
    • 11.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
    • 11.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.8.3. Germany Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.8.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.8.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.9.3. UK Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.9.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.9.5. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.9.6. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.10.3. France Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.10.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.10.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.11.3. Italy Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.11.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.11.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.11.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.12.3. Spain Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.12.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.12.5. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.12.6. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.13.6. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.14.3. Sweden Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.14.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.14.6. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.15.3. Russia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.15.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.15.5. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.15.6. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.16.3. Poland Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.16.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.16.5. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.16.6. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Ophthalmic Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
    • 11.4.4. APAC Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
    • 11.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
    • 11.4.6. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
    • 11.4.7. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.8.3. China Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.8.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.8.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.9.3. India Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.9.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.9.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.10.3. Japan Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.10.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.10.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.11.3. South Korea Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.11.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.11.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.12.3. Australia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.12.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.12.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.14.3. Thailand Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.14.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.14.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.15.3. PhilippinesMarket Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.15.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.15.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Ophthalmic Drugs Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
    • 11.5.4. LATAM Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
    • 11.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
    • 11.5.6. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
    • 11.5.7. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.5.8.3. Brazil Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.5.8.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.5.8.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.5.9.3. Mexico Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.5.9.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.5.9.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.5.10.3. Argentina Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.5.10.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.5.10.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.5.11.3. Colombia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.5.11.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.5.11.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Ophthalmic Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
    • 11.6.4. MEA Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
    • 11.6.5. MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
    • 11.6.6. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
    • 11.6.7. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.9. UAE
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.9.3. UAE Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.9.4. UAE Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.9.5. UAE Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.9.6. UAE Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.10.3. Israel Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.10.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.10.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.11.3. Turkey Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.11.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.11.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.12.3. Algeria Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.12.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.12.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.13.3. Egypt Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.13.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.13.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)

12. Key Vendor Analysis- Ophthalmic Drugs

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Roche (Genentech, Inc.)
    • 12.2.2. Regeneron Pharmaceuticals, Inc.
    • 12.2.3. Bausch Health Companies, Inc.
    • 12.2.4. Merck & Co., Inc.
    • 12.2.5. Novartis AG
    • 12.2.6. Coherus BioSciences, Inc.
    • 12.2.7. AbbVie, Inc. (Allergan)
    • 12.2.8. Pfizer, Inc.
    • 12.2.9. Bayer AG
    • 12.2.10. Santen Pharmaceutical Co., Ltd.
    • 12.2.11. Alcon
    • 12.2.12. Nicox

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us